TMBR Stock - Timber Pharmaceuticals, Inc.
Unlock GoAI Insights for TMBR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $83,177 | $295,738 | $453,810 | $324,646 | $57,000 |
| Gross Profit | $-13,218,781 | $-5,853,848 | $-1,047,323 | $-3,058,018 | $-26,000 |
| Gross Margin | -15892.4% | -1979.4% | -230.8% | -942.0% | -45.6% |
| Operating Income | $-19,235,396 | $-10,650,218 | $-20,211,867 | $-3,644,578 | $-17,228,000 |
| Net Income | $-19,379,450 | $-10,639,146 | $-15,117,614 | $-3,690,136 | $-17,258,000 |
| Net Margin | -23299.0% | -3597.5% | -3331.3% | -1136.7% | -30277.2% |
| EPS | $-9.19 | $-13.15 | $-48.15 | $-29.31 | $-1340.11 |
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Visit WebsiteEarnings History & Surprises
TMBREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 19, 2024 | — | — | — | — |
Q2 2024 | May 13, 2024 | — | — | — | — |
Q1 2024 | Mar 29, 2024 | — | — | — | — |
Q4 2023 | Nov 27, 2023 | $-1.26 | — | — | — |
Q2 2023 | May 15, 2023 | $-1.17 | $-1.32 | -12.8% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-1.50 | $-1.72 | -14.7% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | — | $-1.72 | — | — |
Q3 2022 | Aug 11, 2022 | $-2.00 | $-4.50 | -125.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-2.00 | $-2.50 | -25.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | — | $-2.50 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-2.58 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-4.00 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-4.00 | — | — |
Q2 2021 | May 11, 2021 | — | $-2.67 | — | — |
Q1 2021 | Mar 23, 2021 | — | $-39.50 | — | — |
Q4 2020 | Nov 12, 2020 | — | $7.33 | — | — |
Q3 2020 | Aug 18, 2020 | — | $-67.93 | — | — |
Q2 2020 | Jun 12, 2020 | $-42.00 | $-67.00 | -59.5% | ✗ MISS |
Q1 2020 | Mar 23, 2020 | $-48.00 | $-51.36 | -7.0% | ✗ MISS |
Q4 2019 | Dec 10, 2019 | $-132.00 | $-84.00 | +36.4% | ✓ BEAT |
Latest News
Frequently Asked Questions about TMBR
What is TMBR's current stock price?
What is the analyst price target for TMBR?
What sector is Timber Pharmaceuticals, Inc. in?
What is TMBR's market cap?
Does TMBR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TMBR for comparison